Talk of nine hospitals waiting for their initial supply of a product that is expected to sell for $1k-3k per course (and a $1k govnm subsidy)is enough for me to put $$ in this stock.
Even if ropren is sold at $1000 (min possible) and they only sell 500 courses in the first year, the stock still represents excellent value for money when you consider the growth potential.
